

[For immediate release]

**Bloomage BioTechnology Corporation Limited**  
**華熙生物科技股份有限公司****BLOOMAGE BIOTEC COMMENCES TRADING ON MAIN BOARD OF SEHK**

\* \* \* \*

**SHARES WERE ACTIVELY TRADED****CLOSED AT HK\$1.04 PER SHARE, 4% HIGHER THAN OFFER PRICE**

(Hong Kong, 3 October 2008) – The shares of Bloomage BioTechnology Corporation Limited (“Bloomage BioTec” or the “Group”, Stock Code: 00963), a hyaluronic acid (HA) manufacturer in China, commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited today.

The shares were actively traded with positive price movements during the day. The intra-day high was HK\$1.16 per share and the closing price was HK\$1.04 per share, approximately 4% higher than the offer price of HK\$1.00 per share. A total of approximately 8,922,500 shares were traded, with total transaction value at approximately HK\$9,335,150.

Ms. Zhao Yan, Chairman and Executive Director of Bloomage BioTec, said, “We are pleased with the performance of our share price on the first trading day, mirroring strong investor confidence in the bright prospects of the Group and growth potential of the biotechnology industry. A milestone for the Group, the listing not only allows the international market to gain a better understanding of the Group and HA products, but has also given the Group an international platform to raise funds for upgrading technological capabilities and growing its markets. We are poised to achieve better business performance and more satisfactory returns for shareholders.”

*~ End ~***About Bloomage BioTechnology Corporation Limited (stock code: 00963.HK)**

Bloomage BioTec produces four different grades of hyaluronic acid (“HA”) products of different specifications in China, namely injection, eye drop, cosmetics and food grades. Being the only HA manufacturer in China that obtains the drug manufacturing permit for the production of HA to be used as pharmaceutical excipients, it has over 650 domestic and international customers. HA is a natural hydration factor widely used in pharmaceutical, cosmetic and healthcare products. Riding on its leading R&D capabilities, the Group continues to expand its product portfolio by launching new products, and to increase the yield rate for the production of reliable and high quality HA products.

**FOR ENQUIRIES:****Strategic Financial Relations (China) Limited****Ms. Serine Li (852) 2864 4811**[serine.li@sprg.com.hk](mailto:serine.li@sprg.com.hk)**Ms. Katie Kung (852) 2864 4830**[katie.kung@sprg.com.hk](mailto:katie.kung@sprg.com.hk)**Ms. Janice Au (852) 2864 4874**[janice.au@sprg.com.hk](mailto:janice.au@sprg.com.hk)**Ms. Cathy Zhang (852) 2114 4963**[cathy.zhang@sprg.com.hk](mailto:cathy.zhang@sprg.com.hk)